Menu
Institut de Biologie StructuraleGrenoble / France

Contacts relatifs à cet article / Grossi Laurence

Equipe Poignard

Publications

1. Curiel, T. J., E. C. Krug, M. B. Purner, P. Poignard and R. L. Berens (1993). "Cloned human CD4+ cytotoxic T lymphocytes specific for Toxoplasma gondii lyse tachyzoite-infected target cells." J Immunol 151(4) : 2024-2031.
2. Sattentau, Q. J., J. P. Moore, F. Vignaux, F. Traincard and P. Poignard (1993). "Conformational changes induced in the envelope glycoproteins of the human and simian immunodeficiency viruses by soluble receptor binding." J Virol 67(12) : 7383-7393.
3. Signoret, N., P. Poignard, D. Blanc and Q. J. Sattentau (1993). "Human and simian immunodeficiency viruses : virus-receptor interactions." Trends Microbiol 1(9) : 328-333.
4. Sattentau, Q. J., S. Zolla-Pazner and P. Poignard (1995). "Epitope exposure on functional, oligomeric HIV-1 gp41 molecules." Virology 206(1) : 713-717.
5. Poignard, P., T. Fouts, D. Naniche, J. P. Moore and Q. J. Sattentau (1996). "Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation." J Exp Med 183(2) : 473-484.
6. Poignard, P., P. J. Klasse and Q. J. Sattentau (1996). "Antibody neutralization of HIV-1." Immunol Today 17(5) : 239-246.
7. Debat Zoguereh, D., P. Poignard, A. Sorriaux and P. Brouqui (1997). "[Amphotericin B-intralipid 20% combination. In vivo evaluation of its tolerability]." Ann Med Interne (Paris) 148(1) : 100-102.
8. Parren, P. W., M. C. Gauduin, R. A. Koup, P. Poignard, P. Fisicaro, D. R. Burton and Q. J. Sattentau (1997). "Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design." Immunol Lett 57(1-3) : 105-112.
9. Parren, P. W., M. C. Gauduin, R. A. Koup, P. Poignard, Q. J. Sattentau, P. Fisicaro and D. R. Burton (1997). "Erratum to "Relevance of the antibody response against human immunodeficiency virus type 1 envelope to vaccine design"." Immunol Lett 58(2) : 125-132.
10. Purgus, R., C. Tamalet, P. Poignard, B. Spire, F. George, A. Robert and M. Olmer (1998). "Long-term nonprogressive human immunodeficiency virus-1 infection in a kidney allograft recipient." Transplantation 66(10) : 1384-1386.
11. Mosier, D. E., G. R. Picchio, R. J. Gulizia, R. Sabbe, P. Poignard, L. Picard, R. E. Offord, D. A. Thompson and J. Wilken (1999). "Highly potent RANTES analogues either prevent CCR5-using human immunodeficiency virus type 1 infection in vivo or rapidly select for CXCR4-using variants." J Virol 73(5) : 3544-3550.
12. Poignard, P., R. Sabbe, G. R. Picchio, M. Wang, R. J. Gulizia, H. Katinger, P. W. Parren, D. E. Mosier and D. R. Burton (1999). "Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo." Immunity 10(4) : 431-438.
13. Sakurai, H., R. A. Williamson, J. E. Crowe, J. A. Beeler, P. Poignard, R. B. Bastidas, R. M. Chanock and D. R. Burton (1999). "Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection : significance for subunit vaccines." J Virol 73(4) : 2956-2962.
14. Sattentau, Q. J., M. Moulard, B. Brivet, F. Botto, J. C. Guillemot, I. Mondor, P. Poignard and S. Ugolini (1999). "Antibody neutralization of HIV-1 and the potential for vaccine design." Immunol Lett 66(1-3) : 143-149.
15. Parren, P. W., P. Poignard, H. J. Ditzel, R. A. Williamson and D. R. Burton (2000). "Antibodies in human infectious disease." Immunol Res 21(2-3) : 265-278.
16. Poignard, P., E. O. Saphire, P. W. Parren and D. R. Burton (2001). "gp120 : Biologic aspects of structural features." Annu Rev Immunol 19 : 253-274.
17. Zwick, M. B., M. Wang, P. Poignard, G. Stiegler, H. Katinger, D. R. Burton and P. W. Parren (2001). "Neutralization synergy of human immunodeficiency virus type 1 primary isolates by cocktails of broadly neutralizing antibodies." J Virol 75(24) : 12198-12208.
18. Venturini, S., D. E. Mosier, D. R. Burton and P. Poignard (2002). "Characterization of human immunodeficiency virus type 1 (HIV-1) Gag- and Gag peptide-specific CD4(+) T-cell clones from an HIV-1-seronegative donor following in vitro immunization." J Virol 76(14) : 6987-6999.
19. Labrijn, A. F., P. Poignard, A. Raja, M. B. Zwick, K. Delgado, M. Franti, J. Binley, V. Vivona, C. Grundner, C. C. Huang, M. Venturi, C. J. Petropoulos, T. Wrin, D. S. Dimitrov, J. Robinson, P. D. Kwong, R. T. Wyatt, J. Sodroski and D. R. Burton (2003). "Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1." J Virol 77(19) : 10557-10565.
20. Mascola, J. R., M. G. Lewis, T. C. VanCott, G. Stiegler, H. Katinger, M. Seaman, K. Beaudry, D. H. Barouch, B. Korioth-Schmitz, G. Krivulka, A. Sambor, B. Welcher, D. C. Douek, D. C. Montefiori, J. W. Shiver, P. Poignard, D. R. Burton and N. L. Letvin (2003). "Cellular immunity elicited by human immunodeficiency virus type 1/ simian immunodeficiency virus DNA vaccination does not augment the sterile protection afforded by passive infusion of neutralizing antibodies." J Virol 77(19) : 10348-10356.
21. Pantophlet, R., E. Ollmann Saphire, P. Poignard, P. W. Parren, I. A. Wilson and D. R. Burton (2003). "Fine mapping of the interaction of neutralizing and nonneutralizing monoclonal antibodies with the CD4 binding site of human immunodeficiency virus type 1 gp120." J Virol 77(1) : 642-658.
22. Poignard, P., M. Moulard, E. Golez, V. Vivona, M. Franti, S. Venturini, M. Wang, P. W. Parren and D. R. Burton (2003). "Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies." J Virol 77(1) : 353-365.
23. Venturini, S., G. Allicotti, Y. Zhao, R. Simon, D. R. Burton, C. Pinilla and P. Poignard (2006). "Identification of peptides from human pathogens able to cross-activate an HIV-1-gag-specific CD4+ T cell clone." Eur J Immunol 36(1) : 27-36.
24. Adalid-Peralta, L., V. Godot, C. Colin, R. Krzysiek, T. Tran, P. Poignard, A. Venet, A. Hosmalin, P. Lebon, C. Rouzioux, G. Chene, D. Emilie and A. S. G. Interprim (2008). "Stimulation of the primary anti-HIV antibody response by IFN-alpha in patients with acute HIV-1 infection." J Leukoc Biol 83(4) : 1060-1067.
25. Burton, D. R. and P. Poignard (2009). "HIV : Immune memory downloaded." Nature 458(7238) : 584-585.
26. Hessell, A. J., P. Poignard, M. Hunter, L. Hangartner, D. M. Tehrani, W. K. Bleeker, P. W. Parren, P. A. Marx and D. R. Burton (2009). "Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques." Nat Med 15(8) : 951-954.
27. Hessell, A. J., E. G. Rakasz, P. Poignard, L. Hangartner, G. Landucci, D. N. Forthal, W. C. Koff, D. I. Watkins and D. R. Burton (2009). "Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers." PLoS Pathog 5(5) : e1000433.
28. Simek, M. D., W. Rida, F. H. Priddy, P. Pung, E. Carrow, D. S. Laufer, J. K. Lehrman, M. Boaz, T. Tarragona-Fiol, G. Miiro, J. Birungi, A. Pozniak, D. A. McPhee, O. Manigart, E. Karita, A. Inwoley, W. Jaoko, J. Dehovitz, L. G. Bekker, P. Pitisuttithum, R. Paris, L. M. Walker, P. Poignard, T. Wrin, P. E. Fast, D. R. Burton and W. C. Koff (2009). "Human immunodeficiency virus type 1 elite neutralizers : individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm." J Virol 83(14) : 7337-7348.
29. Walker, L. M., S. K. Phogat, P. Y. Chan-Hui, D. Wagner, P. Phung, J. L. Goss, T. Wrin, M. D. Simek, S. Fling, J. L. Mitcham, J. K. Lehrman, F. H. Priddy, O. A. Olsen, S. M. Frey, P. W. Hammond, G. P. I. Protocol, S. Kaminsky, T. Zamb, M. Moyle, W. C. Koff, P. Poignard and D. R. Burton (2009). "Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target." Science 326(5950) : 285-289.
30. Hessell, A. J., E. G. Rakasz, D. M. Tehrani, M. Huber, K. L. Weisgrau, G. Landucci, D. N. Forthal, W. C. Koff, P. Poignard, D. I. Watkins and D. R. Burton (2010). "Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L." J Virol 84(3) : 1302-1313.
31. Pejchal, R., L. M. Walker, R. L. Stanfield, S. K. Phogat, W. C. Koff, P. Poignard, D. R. Burton and I. A. Wilson (2010). "Structure and function of broadly reactive antibody PG16 reveal an H3 subdomain that mediates potent neutralization of HIV-1." Proc Natl Acad Sci U S A 107(25) : 11483-11488.
32. Walker, L. M., M. D. Simek, F. Priddy, J. S. Gach, D. Wagner, M. B. Zwick, S. K. Phogat, P. Poignard and D. R. Burton (2010). "A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals." PLoS Pathog 6(8) : e1001028.
33. Burton, D. R., A. J. Hessell, B. F. Keele, P. J. Klasse, T. A. Ketas, B. Moldt, D. C. Dunlop, P. Poignard, L. A. Doyle, L. Cavacini, R. S. Veazey and J. P. Moore (2011). "Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody." Proc Natl Acad Sci U S A 108(27) : 11181-11186.
34. Chakrabarti, B. K., L. M. Walker, J. F. Guenaga, A. Ghobbeh, P. Poignard, D. R. Burton and R. T. Wyatt (2011). "Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity." J Virol 85(16) : 8217-8226.
35. Moldt, B., N. Schultz, D. C. Dunlop, M. D. Alpert, J. D. Harvey, D. T. Evans, P. Poignard, A. J. Hessell and D. R. Burton (2011). "A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcgamma receptors to define the role of effector functions in protection against HIV." J Virol 85(20) : 10572-10581.
36. Pejchal, R., K. J. Doores, L. M. Walker, R. Khayat, P. S. Huang, S. K. Wang, R. L. Stanfield, J. P. Julien, A. Ramos, M. Crispin, R. Depetris, U. Katpally, A. Marozsan, A. Cupo, S. Maloveste, Y. Liu, R. McBride, Y. Ito, R. W. Sanders, C. Ogohara, J. C. Paulson, T. Feizi, C. N. Scanlan, C. H. Wong, J. P. Moore, W. C. Olson, A. B. Ward, P. Poignard, W. R. Schief, D. R. Burton and I. A. Wilson (2011). "A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield." Science 334(6059) : 1097-1103.
37. Scheid, J. F., H. Mouquet, B. Ueberheide, R. Diskin, F. Klein, T. Y. Oliveira, J. Pietzsch, D. Fenyo, A. Abadir, K. Velinzon, A. Hurley, S. Myung, F. Boulad, P. Poignard, D. R. Burton, F. Pereyra, D. D. Ho, B. D. Walker, M. S. Seaman, P. J. Bjorkman, B. T. Chait and M. C. Nussenzweig (2011). "Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding." Science 333(6049) : 1633-1637.
38. Walker, L. M., M. Huber, K. J. Doores, E. Falkowska, R. Pejchal, J. P. Julien, S. K. Wang, A. Ramos, P. Y. Chan-Hui, M. Moyle, J. L. Mitcham, P. W. Hammond, O. A. Olsen, P. Phung, S. Fling, C. H. Wong, S. Phogat, T. Wrin, M. D. Simek, G. P. I. Protocol, W. C. Koff, I. A. Wilson, D. R. Burton and P. Poignard (2011). "Broad neutralization coverage of HIV by multiple highly potent antibodies." Nature 477(7365) : 466-470.
39. Walker, L. M., D. Sok, Y. Nishimura, O. Donau, R. Sadjadpour, R. Gautam, M. Shingai, R. Pejchal, A. Ramos, M. D. Simek, Y. Geng, I. A. Wilson, P. Poignard, M. A. Martin and D. R. Burton (2011). "Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque." Proc Natl Acad Sci U S A 108(50) : 20125-20129.
40. Burton, D. R., P. Poignard, R. L. Stanfield and I. A. Wilson (2012). "Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses." Science 337(6091) : 183-186.
41. Falkowska, E., A. Ramos, Y. Feng, T. Zhou, S. Moquin, L. M. Walker, X. Wu, M. S. Seaman, T. Wrin, P. D. Kwong, R. T. Wyatt, J. R. Mascola, P. Poignard and D. R. Burton (2012). "PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4." J Virol 86(8) : 4394-4403.
42. Klein, F., C. Gaebler, H. Mouquet, D. N. Sather, C. Lehmann, J. F. Scheid, Z. Kraft, Y. Liu, J. Pietzsch, A. Hurley, P. Poignard, T. Feizi, L. Morris, B. D. Walker, G. Fatkenheuer, M. S. Seaman, L. Stamatatos and M. C. Nussenzweig (2012). "Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein." J Exp Med 209(8) : 1469-1479.
43. Moldt, B., E. G. Rakasz, N. Schultz, P. Y. Chan-Hui, K. Swiderek, K. L. Weisgrau, S. M. Piaskowski, Z. Bergman, D. I. Watkins, P. Poignard and D. R. Burton (2012). "Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo." Proc Natl Acad Sci U S A 109(46) : 18921-18925.
44. Moldt, B., M. Shibata-Koyama, E. G. Rakasz, N. Schultz, Y. Kanda, D. C. Dunlop, S. L. Finstad, C. Jin, G. Landucci, M. D. Alpert, A. S. Dugast, P. W. Parren, F. Nimmerjahn, D. T. Evans, G. Alter, D. N. Forthal, J. E. Schmitz, S. Iida, P. Poignard, D. I. Watkins, A. J. Hessell and D. R. Burton (2012). "A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced FcgammaRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques." J Virol 86(11) : 6189-6196.
45. Ota, T., C. Doyle-Cooper, A. B. Cooper, M. Huber, E. Falkowska, K. J. Doores, L. Hangartner, K. Le, D. Sok, J. Jardine, J. Lifson, X. Wu, J. R. Mascola, P. Poignard, J. M. Binley, B. K. Chakrabarti, W. R. Schief, R. T. Wyatt, D. R. Burton and D. Nemazee (2012). "Anti-HIV B Cell lines as candidate vaccine biosensors." J Immunol 189(10) : 4816-4824.
46. Poignard, P., B. Moldt, K. Maloveste, N. Campos, W. C. Olson, E. Rakasz, D. I. Watkins and D. R. Burton (2012). "Protection against high-dose highly pathogenic mucosal SIV challenge at very low serum neutralizing titers of the antibody-like molecule CD4-IgG2." PLoS One 7(7) : e42209.
47. Barouch, D. H., J. B. Whitney, B. Moldt, F. Klein, T. Y. Oliveira, J. Liu, K. E. Stephenson, H. W. Chang, K. Shekhar, S. Gupta, J. P. Nkolola, M. S. Seaman, K. M. Smith, E. N. Borducchi, C. Cabral, J. Y. Smith, S. Blackmore, S. Sanisetty, J. R. Perry, M. Beck, M. G. Lewis, W. Rinaldi, A. K. Chakraborty, P. Poignard, M. C. Nussenzweig and D. R. Burton (2013). "Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys." Nature 503(7475) : 224-228.
48. Gach, J. S., H. Quendler, T. Tong, K. M. Narayan, S. X. Du, R. G. Whalen, J. M. Binley, D. N. Forthal, P. Poignard and M. B. Zwick (2013). "A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1." PLoS One 8(8) : e72054.
49. Hoffenberg, S., R. Powell, A. Carpov, D. Wagner, A. Wilson, S. Kosakovsky Pond, R. Lindsay, H. Arendt, J. Destefano, S. Phogat, P. Poignard, S. P. Fling, M. Simek, C. Labranche, D. Montefiori, T. Wrin, P. Phung, D. Burton, W. Koff, C. R. King, C. L. Parks and M. J. Caulfield (2013). "Identification of an HIV-1 clade A envelope that exhibits broad antigenicity and neutralization sensitivity and elicits antibodies targeting three distinct epitopes." J Virol 87(10) : 5372-5383.
50. Julien, J. P., D. Sok, R. Khayat, J. H. Lee, K. J. Doores, L. M. Walker, A. Ramos, D. C. Diwanji, R. Pejchal, A. Cupo, U. Katpally, R. S. Depetris, R. L. Stanfield, R. McBride, A. J. Marozsan, J. C. Paulson, R. W. Sanders, J. P. Moore, D. R. Burton, P. Poignard, A. B. Ward and I. A. Wilson (2013). "Broadly neutralizing antibody PGT121 allosterically modulates CD4 binding via recognition of the HIV-1 gp120 V3 base and multiple surrounding glycans." PLoS Pathog 9(5) : e1003342.
51. Locci, M., C. Havenar-Daughton, E. Landais, J. Wu, M. A. Kroenke, C. L. Arlehamn, L. F. Su, R. Cubas, M. M. Davis, A. Sette, E. K. Haddad, A. V. I. P. C. P. I. International, P. Poignard and S. Crotty (2013). "Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses." Immunity 39(4) : 758-769.
52. Lutje Hulsik, D., Y. Y. Liu, N. M. Strokappe, S. Battella, M. El Khattabi, L. E. McCoy, C. Sabin, A. Hinz, M. Hock, P. Macheboeuf, A. M. Bonvin, J. P. Langedijk, D. Davis, A. Forsman Quigley, M. M. Aasa-Chapman, M. S. Seaman, A. Ramos, P. Poignard, A. Favier, J. P. Simorre, R. A. Weiss, C. T. Verrips, W. Weissenhorn and L. Rutten (2013). "A gp41 MPER-specific llama VHH requires a hydrophobic CDR3 for neutralization but not for antigen recognition." PLoS Pathog 9(3) : e1003202.
53. Sok, D., U. Laserson, J. Laserson, Y. Liu, F. Vigneault, J. P. Julien, B. Briney, A. Ramos, K. F. Saye, K. Le, A. Mahan, S. Wang, M. Kardar, G. Yaari, L. M. Walker, B. B. Simen, E. P. St John, P. Y. Chan-Hui, K. Swiderek, S. H. Kleinstein, G. Alter, M. S. Seaman, A. K. Chakraborty, D. Koller, I. A. Wilson, G. M. Church, D. R. Burton and P. Poignard (2013). "The effects of somatic hypermutation on neutralization and binding in the PGT121 family of broadly neutralizing HIV antibodies." PLoS Pathog 9(11) : e1003754.
54. Blattner, C., J. H. Lee, K. Sliepen, R. Derking, E. Falkowska, A. T. de la Pena, A. Cupo, J. P. Julien, M. van Gils, P. S. Lee, W. Peng, J. C. Paulson, P. Poignard, D. R. Burton, J. P. Moore, R. W. Sanders, I. A. Wilson and A. B. Ward (2014). "Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers." Immunity 40(5) : 669-680.
55. Bouvin-Pley, M., M. Morgand, L. Meyer, C. Goujard, A. Moreau, H. Mouquet, M. Nussenzweig, C. Pace, D. Ho, P. J. Bjorkman, D. Baty, P. Chames, M. Pancera, P. D. Kwong, P. Poignard, F. Barin and M. Braibant (2014). "Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic : a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies." J Virol 88(23) : 13910-13917.
56. Falkowska, E., K. M. Le, A. Ramos, K. J. Doores, J. H. Lee, C. Blattner, A. Ramirez, R. Derking, M. J. van Gils, C. H. Liang, R. McBride, B. von Bredow, S. S. Shivatare, C. Y. Wu, P. Y. Chan-Hui, Y. Liu, T. Feizi, M. B. Zwick, W. C. Koff, M. S. Seaman, K. Swiderek, J. P. Moore, D. Evans, J. C. Paulson, C. H. Wong, A. B. Ward, I. A. Wilson, R. W. Sanders, P. Poignard and D. R. Burton (2014). "Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers." Immunity 40(5) : 657-668.
57. He, L., D. Sok, P. Azadnia, J. Hsueh, E. Landais, M. Simek, W. C. Koff, P. Poignard, D. R. Burton and J. Zhu (2014). "Toward a more accurate view of human B-cell repertoire by next-generation sequencing, unbiased repertoire capture and single-molecule barcoding." Sci Rep 4 : 6778.
58. Hepler, N. L., K. Scheffler, S. Weaver, B. Murrell, D. D. Richman, D. R. Burton, P. Poignard, D. M. Smith and S. L. Kosakovsky Pond (2014). "IDEPI : rapid prediction of HIV-1 antibody epitopes and other phenotypic features from sequence data using a flexible machine learning platform." PLoS Comput Biol 10(9) : e1003842.
59. Ogunniyi, A. O., B. A. Thomas, T. J. Politano, N. Varadarajan, E. Landais, P. Poignard, B. D. Walker, D. S. Kwon and J. C. Love (2014). "Profiling human antibody responses by integrated single-cell analysis." Vaccine 32(24) : 2866-2873.
60. Shingai, M., O. K. Donau, R. J. Plishka, A. Buckler-White, J. R. Mascola, G. J. Nabel, M. C. Nason, D. Montefiori, B. Moldt, P. Poignard, R. Diskin, P. J. Bjorkman, M. A. Eckhaus, F. Klein, H. Mouquet, J. C. Cetrulo Lorenzi, A. Gazumyan, D. R. Burton, M. C. Nussenzweig, M. A. Martin and Y. Nishimura (2014). "Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques." J Exp Med 211(10) : 2061-2074.
61. Sok, D., K. J. Doores, B. Briney, K. M. Le, K. L. Saye-Francisco, A. Ramos, D. W. Kulp, J. P. Julien, S. Menis, L. Wickramasinghe, M. S. Seaman, W. R. Schief, I. A. Wilson, P. Poignard and D. R. Burton (2014). "Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV." Sci Transl Med 6(236) : 236ra263.
62. Doores, K. J., L. Kong, S. A. Krumm, K. M. Le, D. Sok, U. Laserson, F. Garces, P. Poignard, I. A. Wilson and D. R. Burton (2015). "Two classes of broadly neutralizing antibodies within a single lineage directed to the high-mannose patch of HIV envelope." J Virol 89(2) : 1105-1118.
63. Gardner, M. R., L. M. Kattenhorn, H. R. Kondur, M. von Schaewen, T. Dorfman, J. J. Chiang, K. G. Haworth, J. M. Decker, M. D. Alpert, C. C. Bailey, E. S. Neale, Jr., C. H. Fellinger, V. R. Joshi, S. P. Fuchs, J. M. Martinez-Navio, B. D. Quinlan, A. Y. Yao, H. Mouquet, J. Gorman, B. Zhang, P. Poignard, M. C. Nussenzweig, D. R. Burton, P. D. Kwong, M. Piatak, Jr., J. D. Lifson, G. Gao, R. C. Desrosiers, D. T. Evans, B. H. Hahn, A. Ploss, P. M. Cannon, M. S. Seaman and M. Farzan (2015). "AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges." Nature 519(7541) : 87-91.
64. Lee JH, Leaman DP, Kim AS, Torrents de la Peña A, Sliepen K, Yasmeen A, Derking R, Ramos A, de Taeye SW, Ozorowski G, Klein F, Burton DR, Nussenzweig MC, Poignard P, Moore JP, Klasse PJ, Sanders RW, Zwick MB, Wilson IA, Ward AB. (2015) “Antibodies to a conformational epitope on gp41 neutralize HIV-1 by destabilizing the Env spike.” Nat Commun. Sep 25 ;6:8167. doi : 10.1038/ncomms9167.
65. Andrabi R, Voss JE, Liang CH, Briney B, McCoy LE, Wu CY, Wong CH, Poignard P, Burton DR. (2015) “Identification of Common Features in Prototype Broadly Neutralizing Antibodies to HIV Envelope V2 Apex to Facilitate Vaccine Design.“ Immunity. Nov 17 ;43(5):959-73. doi : 10.1016/j.immuni.2015.10.014.
66. Landais E, Huang X, Havenar-Daughton C, Murrell B, Price MA, Wickramasinghe L, Ramos A, Bian CB, Simek M, Allen S, Karita E, Kilembe W, Lakhi S, Inambao M, Kamali A, Sanders EJ, Anzala O, Edward V, Bekker LG, Tang J, Gilmour J, Kosakovsky-Pond SL, Phung P, Wrin T, Crotty S, Godzik A, Poignard P. (2016) “Broadly Neutralizing Antibody Responses in a Large Longitudinal Sub-Saharan HIV Primary Infection” Cohort.PLoS Pathog. Jan 14 ;12(1):e1005369. doi : 10.1371/journal.ppat.1005369. eCollection 2016 Jan.
67. Krumm SA, Mohammed H, Le KM, Crispin M, Wrin T, Poignard P, Burton DR, Doores KJ. (2016) “Mechanisms of escape from the PGT128 family of anti-HIV broadly neutralizing antibodies.” Retrovirology. Feb 2 ;13:8. doi : 10.1186/s12977-016-0241-5.
68. Havenar-Daughton C, Lindqvist M, Heit A, Wu JE, Reiss SM, Kendric K, Bélanger S, Kasturi SP, Landais E, Akondy RS, McGuire HM, Bothwell M, Vagefi PA, Scully E ; IAVI Protocol C Principal Investigators, Tomaras GD, Davis MM, Poignard P, Ahmed R, Walker BD, Pulendran B, McElrath MJ, Kaufmann DE, Crotty S. (2016) “CXCL13 is a plasma biomarker of germinal center activity.” Proc Natl Acad Sci U S A. Mar 8 ;113(10):2702-7. doi : 10.1073/pnas.1520112113. Epub 2016 Feb 23.
69. MacLeod DT, Choi NM, Briney B, Garces F, Ver LS, Landais E, Murrell B, Wrin T, Kilembe W, Liang CH, Ramos A, Bian CB, Wickramasinghe L, Kong L, Eren K, Wu CY, Wong CH ; IAVI Protocol C Investigators & The IAVI African HIV Research Network, Kosakovsky Pond SL, Wilson IA, Burton DR, Poignard P. (2016) “Early Antibody Lineage Diversification and Independent Limb Maturation Lead to Broad HIV-1 Neutralization Targeting the Env High-Mannose Patch.” Immunity. May 17 ;44(5):1215-26. doi : 10.1016/j.immuni.2016.04.016.
70. Sok D, Pauthner M, Briney B, Lee JH, Saye-Francisco KL, Hsueh J, Ramos A, Le KM, Jones M, Jardine JG, Bastidas R, Sarkar A, Liang CH, Shivatare SS, Wu CY, Schief WR, Wong CH, Wilson IA, Ward AB, Zhu J, Poignard P, Burton DR. (2016) “A Prominent Site of Antibody Vulnerability on HIV Envelope Incorporates a Motif Associated with CCR5 Binding and Its Camouflaging Glycans.” Immunity. 2016 Jul 19 ;45(1):31-45. doi : 10.1016/j.immuni.2016.06.026.